Literature DB >> 6084763

Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects.

M Laubie, P Schiavi, M Vincent, H Schmitt.   

Abstract

S 9780, the diacid form of S 9490, inhibited guinea pig plasma angiotensin-converting enzyme (ACE) by 50% (IC50) at a concentration of 2.4 +/- 0.1 nM. A Ki of 1.2 nM was obtained for S 9780 (Dixon-Webb plot) with angiotensin I as a substrate. In rabbits, rats, cats, guinea pigs, and dogs, S 9780 MK 422, S 9490, and MK421 decreased, in a dose-dependent manner, the pressor response to angiotensin I. The rabbit and the rat were the most sensitive species, with ID50 values, respectively, of 2.7 +/- 0.4 and 5.9 +/- 0.3 micrograms/kg i.v. for S 9490 and 1.2 +/- 0.2 and 2.6 +/- 0.8 micrograms/kg i.v. for S 9780. S 9490 induced a dose-dependent decrease in serum ACE activity in rabbits (0.6-20 micrograms/kg i.v.) and guinea pigs (10-100 micrograms/kg i.v.). In conscious rats and dogs S 9490 (0.03-1 mg/kg p.o.) induced a long-lasting inhibition of the angiotensin I-induced pressor response; 40% inhibition was recorded in dogs, 24 h after 1 mg/kg p.o. S 9490 (0.03-0.1 mg/kg i.v.) potentiated the increase in femoral blood flow induced by bradykinin injected into the femoral artery of dogs. In anesthetized dogs, mean blood pressure and heart rate were not changed after sodium restriction, but the cardiac output was markedly decreased. S 9490 (0.1-1 mg/kg i.v.) decreased mean blood pressure both in sodium-restricted and sodium-repleted pentobarbital-anesthetized dogs. However, the lowering effect was more pronounced in sodium-restricted dogs. S 9490 (3 mg/kg p.o.) did not change mean blood pressure in conscious dogs maintained on normal-sodium diet but decreased mean blood pressure in conscious sodium-restricted dogs. Plasma renin activity (PRA) and plasma aldosterone concentration were strongly enhanced in conscious dogs maintained on low-sodium diet.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6084763

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  18 in total

1.  The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects.

Authors:  C L Brown; C I Backhouse; J C Grippat; J P Santoni
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Newer ACE inhibitors. A look at the future.

Authors:  A Salvetti
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

3.  Humoral effects of perindopril in essential hypertension.

Authors:  G A Sagnella; N D Markandu; D R Singer; M G Buckley; M A Miller; G A MacGregor
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Vascular haemodynamic effects of perindopril in essential hypertension.

Authors:  W Littler
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 5.  Perindopril. A review of its pharmacokinetics and clinical pharmacology.

Authors:  R J Macfadyen; K R Lees; J L Reid
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 6.  First-line treatment in hypertension. Role of perindopril.

Authors:  A Zanchetti
Journal:  Drugs       Date:  1990       Impact factor: 9.546

7.  The haemodynamic and humoral effects of treatment for one month with the angiotensin converting enzyme inhibitor perindopril in salt replete hypertensive patients.

Authors:  K R Lees; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Haemodynamic and humoral effects of oral perindopril, an angiotensin converting enzyme inhibitor, in man.

Authors:  K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

9.  Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs.

Authors:  V Richard; B Ghaleh; A Berdeaux; J F Giudicelli
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

10.  Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency.

Authors:  G A Verpooten; P M Genissel; J R Thomas; M E De Broe
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.